Extensions

As a senior US patent analyst on May 13, 2026, I have analyzed the prosecution history and family data for US patent 10,980,934. The following report details the patent's term, continuity, and family relationships.

Patent Term and Expiration

• Patent Term Adjustment (PTA): A review of the patent's prosecution history indicates zero (0) days of Patent Term Adjustment. The application was filed on July 16, 2020, and the patent was issued on April 20, 2021, well within the three-year pendency goal set by the USPTO, thus no "B delay" was accrued.
• Patent Term Extension (PTE): There is no indication that this patent has received any Patent Term Extension under 35 U.S.C. § 156, which typically applies to delays in regulatory review for products like drugs or medical devices.
• Projected Expiration Date: The patent's term is calculated from the filing date of the earliest non-provisional application in its family, which is U.S. Application No. 15/608,183, filed on May 30, 2017. Adding 20 years to this date results in a projected expiration date of May 30, 2037. This date is subject to the timely payment of all required maintenance fees and assumes no terminal disclaimers have been or will be filed.

Continuity and Family Data

This patent is part of a larger family of applications sharing a common priority. The direct lineage and related applications are detailed below.

Direct Parentage:

• This patent, issued from application US 16/931,333 (filed July 16, 2020), is a continuation of:
  • Application US 15/793,339 (filed October 25, 2017), which is a continuation-in-part of:
    • Application US 15/608,183 (filed May 30, 2017), which issued as US Patent 10,758,652.

Child and Sibling Applications (Continuations of the Parent Family):
Based on the provided patent data, the family has been further extended through subsequent continuation applications that claim priority back to the original 2017 filing. These include:

• Application US 17/205,400 (filed March 18, 2021), which is expected to issue as US 12,186,474.
• Application US 18/606,761 (filed March 15, 2024), which published as US 2024/0293604 A1.
• Application US 19/077,384 (filed March 12, 2025), which is expected to issue as US 12,377,204.
• Application US 19/275,431 (filed July 21, 2025), which published as US 2025/0345505 A1.

This extensive family of continuation applications indicates an active strategy by the assignee, Haemonetics Corporation, to build upon the foundational technology described in the parent applications.